{"page_content": "Appendix\n73  |  ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021\nIntroduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen\nACTIVITY METRICUNIT OF\nMEASURECODE REPORTING\nNumber of patients treated Number HC-BP-000 .A Amgen regularly reports market segment share as part of its earnings \ncalls and in its earnings releases published through Business Wire and \nfurnished on Form 8-K .\nNumber of drugs (1) in portfolio and (2) in research and development \n(phases 1-3)Number HC-BP-000 .B Pertinent reporting can be found in the Products and Pipeline sections on \nour website (generally updated quarterly) and the Business section of Part \nI of our 10-K .\nThe inclusion of information contained in this disclosure should not be construed as a characterization regarding the materiality or financial impact of that information .  Please also see our filed \nForm 10-K, and other publicly filed documents available at https://investors  .amgen .com/financials/sec-filings  .\nThis report contains information about Amgen and may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act .  All statements, other than \nstatements of historical facts, may be forward-looking statements  . Amgen cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change \nover time  . Forward-looking statements speak only as of the date they are made, and Amgen assumes no duty to and does not undertake to update forward-looking statements  . Actual results \ncould differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance  . Factors that can cause results to differ, as well \nas additional factors that can affect forward-looking statements, are discussed in Amgen\u2019s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, accessible on the SEC\u2019s website at \nwww  .sec .gov and on Amgen\u2019s investor website at https://investors  .amgen .com and https://investors  .amgen .com/financials/sec-filings  .APPENDIX", "metadata": {"source": "NASDAQ_AMGN_2021.pdf", "page": 72, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}